novartis glp-1 receptor agonist weight management diabetes treatments Heterogeneity in response to agonists in type 2 in real-world clinical practice: insights from the DPV register – an IMI-SOPHIA study | Diabetologia Cardiovascular Protective Properties of GLP-1

This study investigates the effects of allulose, a rare sugar shown to reduce blood glucose, in a rat model of diet-induced obesity and T2D

Grocery list included.

This review summarizes current evidence on the nutritional implications of GLP1-based pharmacotherapy in adults with obesity, including common gastrointestinal adverse events, reduced energy intake, potential macro and micronutrient inadequacies, and risks of lean mass loss

Preclinical and initial human studies suggest that glucagon-like peptide-1 receptor agonists may be promising treatments for alcohol use disorder, but existing approved treatments should be used until safety and efficacy is demonstrated in clinical trials.

Specifically, the primary care data can be requested via application to the CPRD ().

For health-conscious individuals, supplements arent shortcuts, theyre strategic additions